Business Context and Reporting Period
This Form 8-K filing by MiMedx Group, Inc. is dated June 6, 2018. The report addresses a significant corporate governance and accounting matter involving the Audit Committee's conclusion that previously issued financial statements require restatement. The filing also announces the departure of key financial officers and the appointment of an interim Chief Financial Officer.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. Instead, it states that the filing is a "Non-Reliance" notice. Consequently, investors should not rely on any previously reported financial metrics for the fiscal years ended December 31, 2012 through 2016, and interim periods through September 30, 2017. The filing explicitly notes that the restatement will materially impact gross margin, operating income, net income, earnings per share, accounts receivable, and inventories, but specific adjusted figures are not yet available.
Material Changes Versus Prior Period
- Restatement Scope: The Company concluded that financial statements for fiscal years 2012-2016 and interim periods through Q3 2017 must be restated. Additionally, all financial information for Q4 2017 and Q1 2018 is withdrawn and should not be relied upon.
- Revenue Recognition: The restatement is driven by an investigation into sales and distribution practices involving two distributors. Implicit arrangements modified explicit contract terms, requiring revenue to be recognized only when amounts were actually collected rather than when product was sold.
- Internal Controls: The Company now concludes that its controls over financial reporting were ineffective for all "Non-Reliance Periods" due to material weaknesses related to the restatement, reversing previous conclusions of effectiveness for most of these periods.
- Guidance Withdrawal: All prior financial guidance issued for 2018 has been withdrawn.
Guidance, Outlook, and Management Commentary
Management has withdrawn all 2018 financial guidance. The Audit Committee's investigation into sales and distribution practices is ongoing and may broaden the scope of the restatement to include additional distributors, customers, or financial items. The Company does not intend to provide further updates until the investigation is concluded. While the Company is diligently pursuing the completion of the restatement, it cannot currently estimate when the restated financial statements or the 2017 Annual Report on Form 10-K will be filed.
Remedial Actions: The Company has established an Ethics and Compliance Committee and created the positions of Chief Accounting Officer and Internal Auditor to improve accounting and internal control practices.
Personnel Changes:
- Michael J. Senken departed as Chief Financial Officer effective June 6, 2018.
- John E. Cranston departed as Vice President, Corporate Controller and Treasurer effective June 6, 2018.
- Edward J. Borkowski was appointed Interim Chief Financial Officer effective June 6, 2018.
Important Facts for Investor Verification
- Verify the specific impact of the restatement on historical revenue and net income once the restated 10-K and 10-Q filings are released.
- Monitor the progress of the independent investigation into sales and distribution practices to determine if the scope of the restatement expands.
- Confirm the timeline for the filing of the restated financial statements and the 2017 Annual Report.
- Track the appointment of a permanent Chief Financial Officer and Chief Accounting Officer to assess the stability of financial leadership.
- Review the Company's updated disclosure regarding material weaknesses in internal controls over financial reporting.